Literature DB >> 17915573

Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle.

M Vorgerd1, J Zange.   

Abstract

McArdle's disease is caused by genetic defects of the muscle-specific isozyme of glycogen phosphorylase, which block ATP formation from glycogen in skeletal muscle. Creatine supplementation and ketogenic diet have been tested as potential supplements for muscle energy metabolism which may improve muscle symptomatic. Outcome measures were clinical scores describing muscle symptomatic and parameters derived from 31P-MRS examinations on working muscle. In two placebo controlled cross-over studies low dose creatine showed beneficial effects on muscle symptoms and performance whereas high dose creatine distinctly worsened muscle symptomatic in patients. In both studies, however, the absence of an elevation in phosphocreatine indicated the absence of a creatine uptake by the muscle fibre. The effects of creatine on muscle symptomatic may be independent from energy metabolism in muscle. In a case study, ketogenic diet improved muscle symptomatic and performance. However, these effects again did not result in 31P-MRS visible changes in muscle energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915573      PMCID: PMC2949316     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  24 in total

1.  Treatment of glycogenosis type V with ketogenic diet.

Authors:  Verena Busch; Klaus Gempel; Alexandra Hack; Klaus Müller; Matthias Vorgerd; Hanns Lochmüller; Friedrich A M Baumeister
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

2.  Impaired oxidative metabolism increases adenine nucleotide breakdown in McArdle's disease.

Authors:  K Sahlin; N H Areskog; R G Haller; K G Henriksson; L Jorfeldt; S F Lewis
Journal:  J Appl Physiol (1985)       Date:  1990-10

Review 3.  Oral creatine supplementation and athletic performance: a critical review.

Authors:  M S Juhn; M Tarnopolsky
Journal:  Clin J Sport Med       Date:  1998-10       Impact factor: 3.638

4.  Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin.

Authors:  C A Willott; M E Young; B Leighton; G J Kemp; E A Boehm; G K Radda; K Clarke
Journal:  Acta Physiol Scand       Date:  1999-06

5.  Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study.

Authors:  C Kornblum; R Schröder; K Müller; M Vorgerd; J Eggers; M Bogdanow; A Papassotiropoulos; K Fabian; T Klockgether; J Zange
Journal:  Eur J Neurol       Date:  2005-04       Impact factor: 6.089

6.  Aerobic conditioning: an effective therapy in McArdle's disease.

Authors:  Ronald G Haller; Phil Wyrick; Tanja Taivassalo; John Vissing
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

7.  Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study.

Authors:  S Felber; D Skladal; M Wyss; C Kremser; A Koller; W Sperl
Journal:  Neurol Res       Date:  2000-03       Impact factor: 2.448

8.  Phosphocreatine resynthesis is not affected by creatine loading.

Authors:  K Vandenberghe; P Van Hecke; M Van Leemputte; F Vanstapel; P Hespel
Journal:  Med Sci Sports Exerc       Date:  1999-02       Impact factor: 5.411

9.  L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial.

Authors:  L Schöls; J Zange; M Abele; M Schillings; G Skipka; S Kuntz-Hehner; M C P van Beekvelt; W N J M Colier; K Müller; T Klockgether; H Przuntek; M Vorgerd
Journal:  J Neural Transm (Vienna)       Date:  2004-10-12       Impact factor: 3.575

10.  Muscle energy metabolism in McArdle's syndrome by in vivo phosphorus magnetic resonance spectroscopy.

Authors:  Z Argov; W J Bank; J Maris; B Chance
Journal:  Neurology       Date:  1987-11       Impact factor: 9.910

View more
  9 in total

Review 1.  Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).

Authors:  Rosaline Quinlivan; Andrea Martinuzzi; Benedikt Schoser
Journal:  Cochrane Database Syst Rev       Date:  2014-11-12

Review 2.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Muscle diffusion tensor imaging in glycogen storage disease V (McArdle disease).

Authors:  R Rehmann; L Schlaffke; M Froeling; R A Kley; E Kühnle; M De Marées; J Forsting; M Rohm; M Tegenthoff; T Schmidt-Wilcke; M Vorgerd
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

4.  Ketones and inborn errors of metabolism: old friends revisited.

Authors:  Rob C I Wüst; Gepke Visser; Ronald J A Wanders; Riekelt H Houtkooper
Journal:  J Inherit Metab Dis       Date:  2017-01       Impact factor: 4.982

Review 5.  Skeletal muscle disorders of glycogenolysis and glycolysis.

Authors:  Richard Godfrey; Ros Quinlivan
Journal:  Nat Rev Neurol       Date:  2016-05-27       Impact factor: 42.937

Review 6.  Ketogenic diets in patients with inherited metabolic disorders.

Authors:  S Scholl-Bürgi; A Höller; K Pichler; M Michel; E Haberlandt; D Karall
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

Review 7.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

Review 8.  McArdle Disease: New Insights into Its Underlying Molecular Mechanisms.

Authors:  Francisco Llavero; Alazne Arrazola Sastre; Miriam Luque Montoro; Patricia Gálvez; Hadriano M Lacerda; Luis A Parada; José Luis Zugaza
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

Review 9.  Ketogenic diet in neuromuscular and neurodegenerative diseases.

Authors:  Antonio Paoli; Antonino Bianco; Ernesto Damiani; Gerardo Bosco
Journal:  Biomed Res Int       Date:  2014-07-03       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.